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Abstract
One common COVID-19 test is the test for one or more of
the antibodies that the body creates when it encounters the
SARS-CoV-2 virus. Because these tests are often point-ofcare, rapid tests that require only a blood sample, they may
appear to patients to be an easily accessible and useful tool to
guide their actions in the pandemic. However, serologic anti-

body tests should not be offered to patients in normal practice
under nearly any circumstances. They are useful in narrow diagnostic settings in later stage infections, and they serve an
important public health function, but they are not of benefit
to patients and may in fact give false and potentially harmful
information to patients of moderate health literacy.

Introduction

several hours. CLIA tests are also lab-based quantitative tests that can detect multiple types of antibody in
a comparable time frame to the ELISA test. Neutralization assay tests would challenge the antibodies in the
sample with live virus to see how well the antibodies
would actually protect against reinfection (at least in
vitro.) Since this would take days, would require at
least a biosafety level 3 facility due to the use of live
virus [1], and no neutralization assay tests are currently
FDA approved, they will not be considered in this discussion.[2] In addition, for this discussion, it will be assumed that the tests have perfect specificity and sensitivity, which of course is never true; but since the tests
will not be recommended anyway, the fact that they do
not operate as accurately as assumed herein will simply
make them even of less utility.

A point-of-care, rapid serological test for antibodies to
COVID-19 may appear to patients as an easily accessible and useful tool for guiding their actions in the pandemic. However, serologic antibody tests should not
be offered to patients in normal practice under nearly
all circumstances. It is not that the tests are inadequate
at their role of detecting antibodies. The tests are helpful for knowing the spread of the virus, and so have
an important public health role. They can also be an
important diagnostic tool in late stage infections where
the antibodies may be more easily detectible than the
virus. Despite these valid uses, serologic antibody tests
do not benefit patients and may unintentionally provide false and potentially harmful information to patients of moderate health literacy.
The controversy regarding COVID-19 antibody testing
is that we do not know what the presence of antibodies
means for a particular patient. There are four different types of tests: rapid detection tests (RDT), enzymelinked immunosorbent assays (ELISA), Chemiluminescent immunoassay (CLIA), and neutralization assays.[1] RDT tests are point- of-care tests that give rapid
results indicating only the presence or absence of antibodies, but no quantitative information; ELISA tests
are tests that incubate samples with the viral protein to
get an assessment of how many antibodies are present,
usually in a laboratory setting and over the course of
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Framework for Bioethical Debate
A true positive result on an RDT, CLIA, or ELISA test
means, for a given patient, either that they have had a
prior infection or that they are currently infected. An
RDT does not tell how many antibodies are present;
none of the three types tells whether those anti-bodies
are effective in preventing virus growth. Because of
this, a positive antibody test gives no actionable information:
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• It cannot be used to trace contacts, as the presence
of antibodies does not tell us when the person was
infectious.
• It does not tell us anything about whether the test
subject is susceptible to future infection. See, e.g., the
CDC Interim Guidance on serology “definitive data
are lacking, and it remains uncertain whether individuals with antibodies (neutralizing or total) are
protected against reinfection with COVID-19, and
if so, what concentration of antibodies is needed to
confer protection.”[3]
• It does not tell us whether the person is currently
infected or infectious, or whether the infection was
at some time in the past and the patient is now not
contagious. See, e.g., the CDC “Limitations” in their
testing guidelines: “Thus, serologic test results do
not indicate with certainty the presence or absence
of current or previous infection with COVID-19.”[3]
In addition to this lack of direct benefit, a moderately
health-literate patient would likely assume that the
presence of antibodies would indicate a prior (i.e., not
currently active) infection, and protection against future infection. Since neither of these is necessarily true
these assumptions could harm a patient who acts on
them.
Consequently, the recommendations for a person after
a positive antibody test are the same as after a negative antibody test or no test at all. The CDC recommends
(emphasis added):
• Asymptomatic persons who test positive by serologic testing and who are without recent history of a
COVID-19 compatible illness have a low likelihood
of active infection and should follow general recommendations to prevent infection with COVID-19 and
otherwise continue with normal activities, including
work.
• Persons who have had a COVID-19-compatible or
confirmed illness should follow previous guidance regarding resumption of normal activities, including
work.
• There should be no change in clinical practice or use
of personal protective equipment (PPE) by health
care workers and first responders who test positive
for COVID-19 antibody.[3]
Or, to put it another way, a positive test result means
you must approach COVID-19, and its potential to infect you and others, just as you would have prior to the
antibody test. And if a test comes back negative, you
would follow, again, exactly these same guidelines.
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A useful comparison may be drawn here to a more
commonly known circumstance. A 25-year-old male
presenting in primary care with possible appendicitis
with an Alvarado score ≥ 7 or an AIM score ≥ 9 should
not be sent for a CT scan, or even the less expensive
ultrasound.[4] While both of these are highly accurate
tests, the results will not actually be helpful. The Alvarado and AIM scores are obtained by clinical findings and shown to indicate a high (87 to 88%) likelihood of appendicitis. Consequently, even if a CT scan
or ultrasound came back with uncertain or negative results the recommendation should still be to send them
to the ER for immediate surgical evaluation, as even a
short delay in diagnosis and treatment greatly increases
the risk of perforation and sepsis. A positive result
would also indicate sending the patient to the ER; so
even though a CT or ultrasound are accurate diagnostic
tools they do not provide information that should lead
to different actions. Consequently, in normal practice
CT and ultrasound are not recommended in primary
care when the clinical findings are so significant for indicating appendicitis.[4]
A positive antibody test will have the following results:
1. It will confirm a probable infection with COVID-19
at some time in the past, or a still active infection.
2. It may imply to a moderately health-literate test subject that they are not currently infected with, and are
immune to reinfection with, COVID-19 (which may
not be true.)
A negative antibody test will have the following results:
1. It will indicate either that a patient has not been infected with COVID-19 or that they are currently infected but have not yet developed detectable antibodies.
2. It may imply to a moderately health-literate test subject that they are not currently infected with COVID19 (which may not be true).
And in either case:
3. It will make no difference in the recommendations
you make to a patient who is currently not suffering
from any effects of a COVID-like illness.
4. It will make no difference in the recommendations
you make to a patient who is currently suffering
from effects of a COVID-like illness.
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Even assuming perfect specificity and sensitivity, the
results of an antibody test will have no accurate positive impacts and will have potential negative impacts
through potentially misleading patients.
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major challenge to accurately informing patients.[5]

Exceptions in Support of Testing

The pillars of bioethics apply to this unfortunate dynamic clearly:

There is a positive rationale for doing antibody testing
in two restricted areas, neither of which are of the type
discussed above.

1. Beneficence (act in a patient’s best interest): is testing in the patient’s best interest, or is testing in the
interest of public health, science, and the science perfecting COVID antibody testing? Though COVID-19
antibody testing may benefit society and the patient
eventually through the data in bio-samples, this benefit to a patient is very low and carries with it the
risks noted herein.

First, an antibody test can be used in a symptomatic
person suspected to be in the later stages of a COVID19 infection as a diagnostic tool.[3] In later stages of infection (approximately 9-14 days after the onset of illness) testing for viral presence can be unclear, as the
virus may not be present in significant amounts. If antibodies are present, that indicates a likelihood that the
infection is a COVID-19 infection.

2. Non-maleficence (do no harm): are we ensuring that
taking people’s blood samples is done without harm
to the patient? Since a patient might be harmed by
misunderstanding the implications of the results of
the test and will gain very little of note from those
results, it is likely that the harm to the patient will
outweigh the benefits. In addition to concerns about
harms via accidental misinformation that a patient
may infer, there are concerns of privacy common to
biorepositories, including who has custody of the
samples, where the biorepository of samples will be,
and what will be done with the samples besides antibody testing, such as genetic testing.

The second is a public health/epidemiology reason:
presumably, these tests give a good indication of how
widespread the infection has been in a population. This
can give an after the fact analysis of how widespread
asymptomatic infections were, which would give more
information about how deadly the virus is, how far it
has spread, and how effective contact tracing might be
in future waves.

3. Autonomy (respect the patient’s informed choices):
Is it possible to communicate adequately to many
patients that as of now, the antibody tests may not
yield the information they think it yields? In particular, since the concept of antibodies producing resistance to viral infections is the basis of vaccines
that the general public generally recognizes, it may
be very difficult and time-consuming to explain that
this is not known in the case of COVID-19. This may
become easier as news stories regarding the issue enter the public conscious, but at the moment this is a
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These are valid reasons for doing antibody testing, but
these do not significantly benefit the individual being
tested. So as arguments for providing testing to persons concerned about their current or prior infection
status, these do not work well.

Conclusion
Despite the perceived value to patients of knowing
whether they have been previously exposed to and infected by COVID-19, RDT, ELISA, and CLIA serologic
antibody tests ought not be offered or provided in normal practice outside of the exceptions noted above, as
they lead to no actionable patient knowledge and may
lead to dangerous misinformation.
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